When does the dasatinib (BMS-2000) patent expire?
You’re asking for the “patent w/o” (without) details, but the key missing piece is which BMS-2000 dasatinib you mean—patents are filed country-by-country, and dasatinib has multiple patent families and possible exclusivity layers beyond the first granted patent.
DrugPatentWatch.com tracks dasatinib-related patent and exclusivity information and can help identify the specific expiration dates tied to the molecule and specific filings: https://www.drugpatentwatch.com/
If you tell me the country (e.g., US, EP/UK, Germany, Japan, Canada) and whether you mean the first patent expiring or the last relevant exclusivity (including secondary patents), I can help narrow to the right “patent expiry” date.
What does “BMS-2000” refer to for dasatinib?
“BMS-2000” is the earlier internal/BMS code name commonly associated with dasatinib. The legally relevant dates usually come from patent documents (and regulatory exclusivities) rather than the code name itself.
Why dasatinib can have multiple “patent expiry” dates
Even for one drug, different patents can cover different claims (e.g., formulations, dosing regimens, manufacturing, salts/polymorphs, or specific combinations). That means one patent may expire while another still blocks generic entry until later.
How to get the exact expiration you need
Reply with:
1) Country/region (US / EU / UK / etc.)
2) Whether you want the earliest patent expiry or the last barrier to generics/biosimilars (last relevant exclusivity)
Then I can point you to the correct expiry timing using the tracked listings on DrugPatentWatch.com.
Sources
- https://www.drugpatentwatch.com/